Hepatitis b
Conditions
Keywords
immunogenicity, safety, recombinant hepatitis B vaccine, nonresponders
Brief summary
This study is an expanded Phase 2/Phase 3 clinical trial base on the safety data obtained from the phase 1 clinical trial. The purpose of this study is to further evaluate the immunogenicity and safety of 60mcg/30mcg recombinant hepatitis B vaccines in people aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines and to explore the optimizing immunizing dose and immune procedure.
Detailed description
The most effective method to prevent hepatitis B virus infection is to receive the vaccination of hepatitis b vaccine to get the protective antibody anti-HBs. Both the blood-derived hepatitis B vaccine and the recombinant hepatitis B vaccines have been proved to be effective and safe since the application in 1981 and 1989 respectively. Previous passive or active immunization testes indicated that the lowest effective level of anti-HBs for prevention of infection is 10mIU/ml. However there are still some recipients can't generate expected level of anti-HBs after the vaccinations. In adults, there are 5% to 10% recipients will failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines, and those nonresponders are susceptible population even after the vaccinations. In this study, a recipient whose peak period (1 month after vaccination) levels of anti-HBs is lower than 10mIU/ml after finishing the vaccinations of 3 dose 10mcg hepatitis b vaccines is called nonresponders. Nowadays, a lot tests are conducted on nonresponders to help them generate the protective antibody anti-HBs, including increase the antigen dosage of vaccines, increase the injections of vaccines, change the route of inoculation and the use of adjuvant. Unfortunately, these previous studies can not get coincident and persuasive outcomes due to the small sample size and poor representativeness. This study is plan to evaluate the immunogenicity and safety of 60mcg/30mcg recombinant hepatitis B vaccines in people aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines and to provide the scientific evidences for the revaccination strategy in China.
Interventions
BIOLOGICAL60mcg/1.0ml recombinant hepatitis B vaccine
to receive 60mcg/1.0ml recombinant HBV vaccines on day 0, 30 and 60
BIOLOGICAL30mcg/1.0ml recombinant hepatitis B vaccine
to receive 30mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.
BIOLOGICAL10mcg/1.0ml recombinant hepatitis B vaccine
to receive 10mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60
Sponsors
Shenzhen Kangtai Biological Products Co., LTD
Jiangsu Province Centers for Disease Control and Prevention
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No
Inclusion criteria
: Filter period: The subjects to receive first 10mcg recombinant hepatitis B vaccines: * Healthy subjects aged 16 and older as established by medical history and clinical examination * The subjects or their guardians are able to understand and sign the informed consent * Had never received the hepatitis B vaccines * Subjects who can and will comply with the requirements of the protocol Revaccination period: The nonresponders to receive first 60mcg recombinant hepatitis B vaccines: * Healthy subjects aged 16 and older as established by medical history and clinical examination * The subjects or their guardians are able to understand and sign the informed consent * After the routine administration of 10mcg hepatitis B vaccines, the peak period levels of anti-HBs is lower than 10mIU/ml * Subjects with temperature \<37.1°C on axillary setting * Subjects who can and will comply with the requirements of the protocol
Exclusion criteria
Filter period: The subjects to receive first 10mcg recombinant hepatitis B vaccines: * Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine * Family history of seizures or progressive neurological disease * Family history of congenital or hereditary immunodeficiency * Women of pregnancy, lactation or about to be pregnant in 60 days * Autoimmune disease or immunodeficiency * Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with IM injections or blood draws * Any prior administration of administration of immunoglobulins Filter period: The subjects to receive second or/and third 10mcg recombinant hepatitis B vaccines: * Any reaction or hypersensitivity to the recombinant hepatitis B vaccines after the vaccinations * Serious adverse reactions to vaccines * Active infections * Subjects who want to quit the study * Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives Revaccination period: The nonresponders to receive first 60mcg recombinant hepatitis B vaccines: * Qualitative test of Anti-HBs, HBsAg or Anti-HBc on serum is positive * Any reaction or hypersensitivity to the recombinant hepatitis B vaccines after the vaccinations * Family history of seizures or progressive neurological disease * Family history of congenital or hereditary immunodeficiency * Women of pregnancy, lactation or about to be pregnant in 60 days * Autoimmune disease or immunodeficiency * Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with IM injections or blood draws * Any prior administration of immunoglobulins, any other vaccines or experimental drugs in the last 7days * Any active infections and received any antibiotic or anti-virus treatments in the last 7 days * Had a fever in the last 3 days, with temperature ≥37.1°C * Participate in another clinical trials * Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives Revaccination period: The nonresponders to receive second or/and third 60mcg recombinant hepatitis B vaccines: * Any reaction or hypersensitivity to the recombinant hepatitis B vaccines after the vaccinations * Serious adverse reactions to vaccines * Active infections * Subjects who want to quit the study * Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Immunogenicity of Recombinant Hepatitis B Vaccines in Nonresponders | one month after the second vaccination | Quantitative detection of anti-HBs using ratio-immunity method on serum obtained one month after second vaccination |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Immunogenicity of Recombinant Hepatitis B Vaccines in Nonresponders | one month after the first vaccination | Quantitative detection of anti-HBs using ratio-immunity method on serum obtained one month after first vaccination |
| the Safety of Recombinant Hepatitis B Vaccines in Nonresponders | within the first 30 days after first vaccination | assessment of the local and systemic adverse reaction within the first 30 days after first vaccination |
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| 60mcg/1.0ml Recombinant Hepatitis B Vaccine 600 participants aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines to receive 60mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60. | 434 |
| 30mcg/1.0ml Recombinant Hepatitis B Vaccine 600 participants aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines to receive 30mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60. | 435 |
| 10mcg/1.0ml Recombinant Hepatitis B Vaccine 300 participants aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines to receive 10mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60. | 222 |
| Total | 1,091 |
Baseline characteristics
| Characteristic | 60mcg/1.0ml Recombinant Hepatitis B Vaccine | 30mcg/1.0ml Recombinant Hepatitis B Vaccine | 10mcg/1.0ml Recombinant Hepatitis B Vaccine | Total |
|---|---|---|---|---|
| Age Continuous | 42.7 years | 43.3 years | 42.6 years | 43.0 years |
| Sex: Female, Male Female | 226 Participants | 220 Participants | 115 Participants | 561 Participants |
| Sex: Female, Male Male | 208 Participants | 215 Participants | 107 Participants | 530 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 0 / 434 | 0 / 435 | 0 / 222 |
| serious Total, serious adverse events | 0 / 434 | 0 / 435 | 0 / 222 |
Outcome results
Primary
Immunogenicity of Recombinant Hepatitis B Vaccines in Nonresponders
Quantitative detection of anti-HBs using ratio-immunity method on serum obtained one month after third vaccination
Time frame: one month after the third vaccination
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 60mcg/1.0ml Recombinant Hepatitis B Vaccine | Immunogenicity of Recombinant Hepatitis B Vaccines in Nonresponders | 411 participants |
| 30mcg/1.0ml Recombinant Hepatitis B Vaccine | Immunogenicity of Recombinant Hepatitis B Vaccines in Nonresponders | 394 participants |
| 10mcg/1.0ml Recombinant Hepatitis B Vaccine | Immunogenicity of Recombinant Hepatitis B Vaccines in Nonresponders | 187 participants |
Primary
Immunogenicity of Recombinant Hepatitis B Vaccines in Nonresponders
Quantitative detection of anti-HBs using ratio-immunity method on serum obtained one month after second vaccination
Time frame: one month after the second vaccination
Population: Accroding to Protocol set
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 60mcg/1.0ml Recombinant Hepatitis B Vaccine | Immunogenicity of Recombinant Hepatitis B Vaccines in Nonresponders | 394 participants |
| 30mcg/1.0ml Recombinant Hepatitis B Vaccine | Immunogenicity of Recombinant Hepatitis B Vaccines in Nonresponders | 371 participants |
| 10mcg/1.0ml Recombinant Hepatitis B Vaccine | Immunogenicity of Recombinant Hepatitis B Vaccines in Nonresponders | 180 participants |
Secondary
Immunogenicity of Recombinant Hepatitis B Vaccines in Nonresponders
Quantitative detection of anti-HBs using ratio-immunity method on serum obtained one month after first vaccination
Time frame: one month after the first vaccination
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 60mcg/1.0ml Recombinant Hepatitis B Vaccine | Immunogenicity of Recombinant Hepatitis B Vaccines in Nonresponders | 367 participants |
| 30mcg/1.0ml Recombinant Hepatitis B Vaccine | Immunogenicity of Recombinant Hepatitis B Vaccines in Nonresponders | 331 participants |
| 10mcg/1.0ml Recombinant Hepatitis B Vaccine | Immunogenicity of Recombinant Hepatitis B Vaccines in Nonresponders | 158 participants |
Secondary
the Safety of Recombinant Hepatitis B Vaccines in Nonresponders
assessment of the local and systemic adverse reaction within the first 30 days after first vaccination
Time frame: within the first 30 days after first vaccination
Secondary
the Safety of Recombinant Hepatitis B Vaccines in Nonresponders
assessment of the local and systemic adverse reaction within the first 30 days after second vaccination
Time frame: within the first 30 days after second vaccination
Secondary
the Safety of Recombinant Hepatitis B Vaccines in Nonresponders
assessment of the local and systemic adverse reaction within the first 30 days after third vaccination
Time frame: within the first 30 days after third vaccination